ArticleClinical ophthalmology (Auckland, N.Z.)2026
Ocular Surface Changes and Glaucoma: A Prospective Contralateral Study of IOP-Reducing Eyedrops versus iStent Inject Surgery.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Should Schlemm Canal-Based MIGS Be Combined with Cataract Surgery in Patients Receiving Topical Glaucoma Therapy? A Cataract Surgeon-Oriented Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare ocular surface outcomes between interventional glaucoma treatment with trabecular micro-bypass stent implantation and continued topical intraocular pressure-lowering therapy. Patients and Methods: A prospective, single-center, contralateral-eye study of patients with bilateral, mild-to-moderate open-angle glaucoma undergoing implantation of the iStent inject in the study eye, while the fellow eye (control eye) continued topical medications. Just over half the eyes in both groups underwent phacoemulsification. Ocular surface parameters were evaluated using objective tests and validated symptom questionnaires at baseline and at 1, 3, and 6 months. Results: Fifty-six eyes were included, 28 in each group. At 6 months, medication use reduced significantly in study eyes (from 1.9±1.0 preoperatively to 0.4±0.6; p<0.001), but not in control eyes (from 1.5±0.9 to 1.4±0.8; p=0.168). Study eyes demonstrated significant improvements in keratograph bulbar redness score (2.4±0.6 to 2.0±0.4; p=0.003), and Oxford ocular surface staining (OSS) score (1.6±1.2 to 0.7±1.0; p<0.001) while control eyes did not; improvements in bulbar redness and OSS scores were significantly greater in study eyes (p=0.005 and p=0.045, respectively). Patient-reported symptoms improved significantly: OSDI (Ocular Surface Disease Index) scores decreased from 18.4 ± 16.4 to 9.3 ± 8.9 (p=0.007) and SPEED (Standard Patient Evaluation of Eye Dryness) II scores decreased from 8.0 ± 7.8 to 4.5 ± 4.1 (p=0.005). Conclusion: Interventional glaucoma treatment with trabecular micro-bypass stent implantation significantly reduced medication burden, which was associated with improved signs and symptoms of ocular surface disease at 6 months. Compared to fellow eyes on topical therapy, stent-treated eyes showed better outcomes in selected ocular surface parameters, supporting the benefits of an interventional approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.